New injectable drug aims to tame blood sugar in type 2 diabetes

NCT ID NCT06650007

Completed Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether an experimental injectable drug called HRS9531 can help adults with type 2 diabetes achieve better blood sugar control when diet and exercise alone are not enough. Participants receive either HRS9531 or a placebo for 36 weeks. The main goal is to see if the drug lowers HbA1c, a key measure of long-term blood sugar, and also to check for weight loss and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental injectable drug called HRS9531
What this could lead to: If successful, HRS9531 could offer a new treatment option for people with type 2 diabetes to better control blood sugar and possibly lose weight.
What could go wrong: This is a mid-stage trial with 218 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Show contact details

Locations

The Second Xiangya Hospital of Central South University

Changsha, Hunan, 410100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.